基石药业-B(02616.HK)与纽交所上市Pfizer进行战略合作
格隆汇 9 月 30日丨基石药业-B(02616.HK)发布公告，2020年9月30日(交易时段前)，公司与Pfizer Corporation订立股份认购协议，据此，Pfizer Corporation已有条件同意按认购价每股约13.37港元认购股份，于最后交易日，联交所所报收市价为9.30港元。
根据股份认购协议，公司将向Pfizer Corporation配发及发行合共约1.159亿股的新股份，认购股份占公司经配发及发行认购股份扩大后的已发行股本9.90%。配发及发行认购股份的所得款项总额将为约2亿美元(相当于约15.5亿港元)，该所得款项总额将根据合作协议载列的条款及条件(除非合作协议订约各方另有协定)用于为合作协议项下的开发活动提供资金。
同日，集团与Pfizer Investment订立合作协议，据此，集团与Pfizer Investment已同意主要就以下事项进行战略合作，自股份认购协议完成起生效。(i)CS1001合作，据此，集团已同意授予Pfizer Investment独家许可，以在中国商业化CS1001(公司的一种抗PD-L1单克隆抗体)；(ii)额外资产合作，据此，订约各方已同意合作开发及商业化合作地区内的额外资产；及(iii)授权资产合作，据此，订约各方已同意共同收购或授权授权资产，并开发及商业化合作地区内的该等授权资产。
Pfizer Corporation及Pfizer Investment为Pfizer Inc.(一家于特拉华州注册成立并于纽约交易所上市的公司)的间接全资附属公司。Pfizer运用科学及其全球资源以改善每个年龄段人们的健康状况。Pfizer致力于为人们探索、研发及生产医疗卫生产品(包括创新药及疫苗)的过程中建立质量、安全及价值标准。发达及新兴市场的Pfizer团队携手工作，推进健康、预防、医疗及治疗，挑战集团这个时代最为棘手的疾病。肩负着作为世界领先生物制药公司的责任，Pfizer亦与医疗卫生提供商、政府及当地社区合作，支持向世界各地更多人提供可靠及可承付的医疗卫生服务。170多年来，Pfizer一直努力改善其客户的生活。
公告表示，公司与Pfizer Corporation订立认购事项，与Pfizer Investment进行战略合作，有助于在公司向全面的生物制药公司转型时，推进公司的战略、商业及财务目标。特别是，认购事项及战略合作将加强公司为CS1001的开发提供资金，建立完整商业化基础设施，及专注于开发同类首创及同类最优的资产的能力。
CS1001是基石药业开发的、有望成为同类最优的一款PD-L1抗体，其潜在适应症涵盖肺癌、胃癌和食管癌等多个中国高发癌症类型。此项合作为基石药业进一步开发CS1001提供了资金支持。与此同时，Pfizer Investment获得基石药业的授权，在中国独家负责CS1001的商业化经营，并将发挥其行业领先的商业化能力，让该创新疗法更快惠及中国更广大地区的医生和患者。合作还将使基石药业和 Pfizer Investment能在大中华地区开发和商业化更多创新肿瘤产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
